MiMedx Deferred Long Term Liab from 2010 to 2024
| MDXG Stock | USD 9.22 0.16 1.77% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 0.0 | Current Value 1.7 M | Quarterly Volatility 343 K |
Check MiMedx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MiMedx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 6.8 M or Selling General Administrative of 123.2 M, as well as many indicators such as Price To Sales Ratio of 3.02, Dividend Yield of 0.0 or PTB Ratio of 6.8. MiMedx financial statements analysis is a perfect complement when working with MiMedx Valuation or Volatility modules.
MiMedx | Deferred Long Term Liab |
Latest MiMedx's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of MiMedx Group over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. MiMedx's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MiMedx's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
MiMedx Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 253,304 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 74.64 | |
| Mean Deviation | 168,869 | |
| Median | 354,000 | |
| Standard Deviation | 189,056 | |
| Sample Variance | 35.7B | |
| Range | 487K | |
| R-Value | 0.80 | |
| Mean Square Error | 14.1B | |
| R-Squared | 0.63 | |
| Significance | 0.0004 | |
| Slope | 33,631 | |
| Total Sum of Squares | 500.4B |
MiMedx Deferred Long Term Liab History
About MiMedx Financial Statements
MiMedx stakeholders use historical fundamental indicators, such as MiMedx's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although MiMedx investors may analyze each financial statement separately, they are all interrelated. For example, changes in MiMedx's assets and liabilities are reflected in the revenues and expenses on MiMedx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MiMedx Group. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 407.1 K | 427.5 K |
Currently Active Assets on Macroaxis
When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:Check out the analysis of MiMedx Correlation against competitors. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.57 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.